David A Bond

Trials

Studies that name David A Bond as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:43 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05821088 · Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

  David Bond, MD · active not recruiting · Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma · principal investigator
• Ph2
  NCT03749018 · Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

  David Bond, MD · active not recruiting · Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.